Max joined Novo Ventures in 2022 and is based in the London office.
Previously, Max was a Principal at BGV, a life science venture capital firm specialized in early stage companies, where he focused on investments in Europe, the United States, and led multiple company creation initiatives. Max served on the Board of Directors of Complement Therapeutics and was an observer on the Board of Directors of Dualyx, Link Immunotherapeutics, and VarmX. Prior to BGV, he worked in various operational roles at Eden Biologics, a biologics CDMO, and at Hummingbird Bioscience, a company leveraging systems biology for antibody discovery and development.
Max studied protein engineering for applications in regenerative medicine as an A*STAR fellow. He holds a PhD in Chemical and Biomolecular Engineering from the National University of Singapore, a BS in Biochemical Engineering from the University of California Irvine, and a Master’s in Business Administration from INSEAD.